The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409).
 
Cristina I. Truica
Stock and Other Ownership Interests - GlaxoSmithKline
Honoraria - Daiichi Sankyo/Lilly; Puma Biotechnology; Seagen
Consulting or Advisory Role - Novartis
Speakers' Bureau - Daiichi Sankyo/Lilly; Puma Biotechnology; Seagen; Seagen
Research Funding - Novartis
 
Amanda Marie Parkes
Employment - Amgen
Consulting or Advisory Role - Daiichi Sankyo Inc.; Deciphera; The Dedham Group
 
Oana Cristina Danciu
Consulting or Advisory Role - Macrogenics
Research Funding - Pfizer; Sanofi
 
Monali K. Vasekar
No Relationships to Disclose
 
Kent Hoskins
Employment - Lilly (I)
Research Funding - Abbvie (Inst); Merck Sharp & Dohme (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst)
Other Relationship - Agendia
 
Kari Braun Wisinski
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; Eisai; Eisai; Genomic Health; Novartis Institutes for BioMedical Research; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Context Therapeutics (Inst); Genentech (Inst); Novartis (Inst); Oncoceutics (Inst); Pfizer; Pfizer; Sanofi (Inst)